欢迎访问中国现代中药网站

作者中文名	作者英文名	单位中文名	单位英文名	E-Mail
刘妍如	LIU Yan-ru	陕西中医药大学陕西省中药资源产业化协同创新中心/秦药特色资源研究开发国家重点实验室（培育）/陕西省创新药物研究中心，陕西咸阳712083	Shaanxi Collaborative Innovation Center of Chinese Medicine Resources Industrialization/State Key Laboratory of Research & Development of Characteristic Qin Medicine Resources（Cultivation）/Shaanxi Innovative Drug Research Center，Shaanxi University of Chinese Medicine，Xianyang 712083，China
唐志书	TANG Zhi-shu	陕西中医药大学陕西省中药资源产业化协同创新中心/秦药特色资源研究开发国家重点实验室（培育）/陕西省创新药物研究中心，陕西咸阳712083	Shaanxi Collaborative Innovation Center of Chinese Medicine Resources Industrialization/State Key Laboratory of Research & Development of Characteristic Qin Medicine Resources（Cultivation）/Shaanxi Innovative Drug Research Center，Shaanxi University of Chinese Medicine，Xianyang 712083，China	唐志书，教授，研究方向：中药制剂制备技术与质量分析研究；Tel：（029）38185060，E-mail：tzs6565@163.com
宋忠兴	SONG Zhong-xing	陕西中医药大学陕西省中药资源产业化协同创新中心/秦药特色资源研究开发国家重点实验室（培育）/陕西省创新药物研究中心，陕西咸阳712083	Shaanxi Collaborative Innovation Center of Chinese Medicine Resources Industrialization/State Key Laboratory of Research & Development of Characteristic Qin Medicine Resources（Cultivation）/Shaanxi Innovative Drug Research Center，Shaanxi University of Chinese Medicine，Xianyang 712083，China
周瑞	ZHOU Rui	陕西中医药大学陕西省中药资源产业化协同创新中心/秦药特色资源研究开发国家重点实验室（培育）/陕西省创新药物研究中心，陕西咸阳712083	Shaanxi Collaborative Innovation Center of Chinese Medicine Resources Industrialization/State Key Laboratory of Research & Development of Characteristic Qin Medicine Resources（Cultivation）/Shaanxi Innovative Drug Research Center，Shaanxi University of Chinese Medicine，Xianyang 712083，China
许洪波	XU Hong-bo	陕西中医药大学陕西省中药资源产业化协同创新中心/秦药特色资源研究开发国家重点实验室（培育）/陕西省创新药物研究中心，陕西咸阳712083	Shaanxi Collaborative Innovation Center of Chinese Medicine Resources Industrialization/State Key Laboratory of Research & Development of Characteristic Qin Medicine Resources（Cultivation）/Shaanxi Innovative Drug Research Center，Shaanxi University of Chinese Medicine，Xianyang 712083，China
于金高	YU Jin-gao	陕西中医药大学陕西省中药资源产业化协同创新中心/秦药特色资源研究开发国家重点实验室（培育）/陕西省创新药物研究中心，陕西咸阳712083	Shaanxi Collaborative Innovation Center of Chinese Medicine Resources Industrialization/State Key Laboratory of Research & Development of Characteristic Qin Medicine Resources（Cultivation）/Shaanxi Innovative Drug Research Center，Shaanxi University of Chinese Medicine，Xianyang 712083，China
张君威	ZHANG Jun-wei	陕西中医药大学陕西省中药资源产业化协同创新中心/秦药特色资源研究开发国家重点实验室（培育）/陕西省创新药物研究中心，陕西咸阳712083	Shaanxi Collaborative Innovation Center of Chinese Medicine Resources Industrialization/State Key Laboratory of Research & Development of Characteristic Qin Medicine Resources（Cultivation）/Shaanxi Innovative Drug Research Center，Shaanxi University of Chinese Medicine，Xianyang 712083，China
王昌利	WANG Chang-li	陕西中医药大学陕西省中药资源产业化协同创新中心/秦药特色资源研究开发国家重点实验室（培育）/陕西省创新药物研究中心，陕西咸阳712083	Shaanxi Collaborative Innovation Center of Chinese Medicine Resources Industrialization/State Key Laboratory of Research & Development of Characteristic Qin Medicine Resources（Cultivation）/Shaanxi Innovative Drug Research Center，Shaanxi University of Chinese Medicine，Xianyang 712083，China
马虎强	MA Hu-qiang	陕西海天制药有限公司，陕西咸阳712046	Shaanxi Haitian Pharmaceutical Limited Company，Xianyang 712046，China

基金项目:2020年度咸阳市重点研发计划“新型冠状病毒肺炎疫情应急防治”科技专项；陕西省三秦学者创新团队（陕组通字［2018］34 号）；陕西省“特支计划”青年拔尖人才项目（陕组通字［2018］33 号）

中文摘要:目的：探索四季抗病毒合剂治疗小儿新型冠状病毒肺炎（COVID-19）的物质基础和潜在机制。方法：本研究以四季抗病毒合剂治疗小儿COVID-19的可行性为切入点，首先对四季抗病毒合剂的临床用药进行meta分析，然后采用网络药理学方法对抗炎成分、靶点和作用机制进行了探索性研究。最后通过分子对接技术，筛选对新型冠状病毒3CL水解酶有抑制作用的活性成分。结果：Meta分析结果显示，四季抗病毒合剂在治疗小儿呼吸系统感染方面具有较好的疗效和安全性，是具有治疗COVID-19潜力的复方。通过构建的“中药-成分-疾病-靶点”网络，筛选得到与干预COVID-19相关的活性成分88个，相关靶点24个。分子对接结果显示，黄酮类成分是四季抗病毒合剂中主要的抗病毒成分。结论：综合结果预测，四季抗病毒合剂可通过调控白介素-17（IL-17）信号通路和花生四烯酸代谢通路，缓解病毒感染诱发的全身免疫反应和炎症效应，达到“治标”作用；还可能通过抑制3CL水解酶，达到干扰病毒复制的“治本”作用。

中文关键词:新型冠状病毒新型冠状病毒肺炎四季抗病毒合剂 meta 分析网络药理学分子对接

Feasibility Analysis of Siji Kangbingdu Mixture for Treatment of Children COVID-19

Abstract:Objective：This paper is to evaluate Siji Kangbingdu Mixture effectiveness and safety and explore its mechanisms in treatment of children COVID-19.Methods：Firstly，we conducted a meta-analysis for Siji Kangbingdu Mixture efficacy and safety in the treatment of children respiratory system infections.Secondly，we performed network pharmacology method to screen active compounds and targets，and explore potential anti-virus mechanism.Finally，we used molecular docking model to evaluate the binding abilities between active compounds and 2019 novel coronavirus （2019-nCoV，SARS-CoV-2） 3CL protease receptor-binding domain （PBD ID 6LU7），which involving in mediating viral replication and transcription functions.Results：The meta-analysis showed that Siji Kangbingdu Mixture had potential power to be an outstanding drug with better effectiveness and safety，compared to chemical anti-virus drugs.According to constructed ′herb-compounds-disease-target′ network analysis，there were 88 compounds and 24 targets which had closely linked with COVID-19.At last，the molecular docking results revealed that 12 of the 88 compounds were identified with higher docking score rank against 2019-nCoV 3CL protease，and most of them were attributed to flavonoids.Conclusion：Taken together，we predict that the Siji Kangbingdu Mixture treatment has a ′win-win′ mechanism，not only for symptoms alleviation，but also for permanent rescue.The mechanism may relate to IL-17 signaling pathway and arachidonic acid metabolism pathway regulation in systemic immune response and inflammation，and it could also interfere novel coronavirus replication by inhibiting 3CL protease.

keywords:2019-nCoV （SARS-CoV-2） COVID-19 Siji Kangbingdu Mixture meta-analysis network pharmacology molecular docking

查看全文查看/发表评论下载PDF阅读器